Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.53 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.51 |
| ▸ | GRM5 | P41594 | 8/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 3/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29744751 | 1.00 | PDK4 (0.54) | PDK4NR1H2GRM1GRM5HTR6 | |
| Bicarbonate SCHEMBL29947017 | 0.96 | PDK4 (0.51) | PDK4NR1H2GRM1GRM5HTR6 | |
| SCHEMBL30822385 | 0.91 | PDK4 (0.54) | PDK4NR1H2GRM1GRM5HTR6 | |
| SCHEMBL27208421 | 0.91 | PDK4 (0.54) | PDK4NR1H2GRM1GRM5HTR6 | |
| SCHEMBL30120331 | 0.90 | NR1H2 (0.52) | PDK4NR1H2GRM1GRM5HTR6 | |
| SCHEMBL13993111 | 0.88 | GRM1 (0.57) | PDK4GRM1GRM5HTR6JAK1 | |
| SCHEMBL24310174 | 0.87 | PDK4 (0.55) | PDK4GRM1GRM5HTR6JAK1 | |
| SCHEMBL29566983 | 0.87 | PDK4 (0.55) | PDK4GRM1GRM5HTR6JAK1 | |
| SCHEMBL29744827 | 0.87 | PDK4 (0.55) | PDK4NR1H2GRM1GRM5HTR6 | |
| SCHEMBL1811363 | 0.87 | PDK4 (0.55) | PDK4NR1H2GRM1GRM5HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4681715-A2 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4076450-B1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS INC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12486290-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250270234-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12371442-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250115580-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-20130303510-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2013170115-A1 | PYRIDAZINE AND PYRIDINE DERIVATIVES AS NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20050054683-A1 | Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings | HUTCHINSON DOUGLAS K (US) | 2005-03-10 | — | — | US | disclosed |
| US-6358942-B1 | MICROBIOCIDES AND BACTERICIDES FOR TREATING GRAMPOSITIVE, BACTEROIDES, CLOSTRIDIUM, MYCOBACTERIUM, STAPHYLOCOCCUS AND STREPTOCOCCUS INFECTIONS | PHARMACIA & UPJOHN COMPANY | 2002-03-19 | — | — | US | disclosed |
| US-6313307-B1 | DEBLOCKING, DEPROTECTING; CATALYTIC HYDROGENATION, ALKYLATION; PREPARING MICROBIOCIDES AGAINST STAPHYLOCOCCUS, STREPTOCOCCUS, MYCOBACTERIUM, AND CLOSTRIDIUM | PHARMACIA & UPJOHN COMPANY | 2001-11-06 | — | — | US | disclosed |
| EP-0856002-B1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | UPJOHN CO (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6166056-A | Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings | PHARMACIA (US) | 2000-12-26 | — | — | US | disclosed |
| US-6051716-A | ANTIMICROBIAL AGENTS | PHARMACIA & UPJOHN, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-6043266-A | MICROBIOCIDES TREATING GRAM-POSITIVE BACTERIA INFECTIONS AND PERSONS WITH AIDS | PHARMACIA & UPJOHN COMPANY (US) | 2000-03-28 | — | — | US | disclosed |
| US-5968962-A | ANTIMICROBIAL AGENTS; EFFECTIVE AGAINST GRAMPOSITIVE BACTERIA | PHARMACIA & UPJOHN COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | PDK4 4425/4885NR1H2 473/4885GRM1 1349/4885 |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | BRAF, NRAS, KRAS | PDK4 2334/4885NR1H2 3983/4885GRM1 4618/4885 |
| US-12486290-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | PDK4 2244/4885NR1H2 2023/4885GRM1 3294/4885 |
| US-20250270234-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | PDK4 2244/4885NR1H2 2023/4885GRM1 3294/4885 |
| US-20130303510-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | PDK4 816/4885NR1H2 371/4885GRM1 2429/4885 |
| US-20260014147-A1 | STAT6 DEGRADERS | STAT6, NCOR1, CBR1 | PDK4 1772/4885NR1H2 137/4885GRM1 1571/4885 |
| US-20250115580-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | BRAF, NRAS, KRAS | PDK4 2334/4885NR1H2 3983/4885GRM1 4618/4885 |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | PDK4 4534/4885NR1H2 1251/4885GRM1 3124/4885 |
| US-20050054683-A1 | Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings | CBR1, NCOR1, RCOR1 | PDK4 1769/4885NR1H2 13/4885GRM1 257/4885 |
| US-12371442-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | PDK4 2244/4885NR1H2 2023/4885GRM1 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.